05.03.2013 • NewsPfizerlawsuitspatents

Pfizer Gets Celebrex Patent Extension

U.S. regulators granted Pfizer a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on Tuesday.

That will give Pfizer an additional 1 1/2 years of selling a drug that had U.S. sales of more than $1.7 billion in 2012, before cheaper generic versions begin to hit the market at the end of 2015. Branded drugs can quickly lose upwards of 80% of sales once multiple generic versions become widely available.

The original basic patent for Celebrex - known chemically as celecoxib - expires on May 30, 2014, including six months of pediatric exclusivity for testing the drug in children. But the U.S. Patent & Trademark Office agreed to the reissued patent covering methods of treating arthritis and other approved conditions, Pfizer said.

Pfizer said it filed lawsuits against several generic drugmakers that are seeking permission from the U.S. Food and Drug Administration to sell a generic version of the drug in the United States beginning in May 2014.

Pfizer said it sued Teva Pharmaceutical Industries; Mylan; Watson Pharmaceuticals, which has since changed its name to Actavis; Lupin Pharmaceuticals; and Apotex to try to prevent them from selling their generic Celebrex until the new patent expires on Dec. 2, 2015.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.